J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
Koji Sasaki,Hagop M. Kantarjian,William G. Wierda,Farhad Ravandi-Kashani,Jeffrey L. Jorgensen,Sa A. Wang,Joseph D. Khoury,Naval Daver,Jan A. Burger,Courtney D. Di Nardo,Nitin Jain,Nicholas J. Short,Zeev Estrov,Marina Konopleva,Maro Ohanian Do,Guillermo Garcia-Manero,Tapan M. Kadia,Yesid Alvarado-Valero,Musa Yilmaz,Sherry Pierce,Rebecca Garris,April Ingram,Jorge E. Cortes,Susan OʼBrien,Elias Jabbour +24 more
TL;DR: Hyper‐CMAD with liposomal vincristine is safe and demonstrated high response and survival rates in newly diagnosed ALL.
Journal ArticleDOI
CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
Journal ArticleDOI
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
Paolo Strati,Michael J. Keating,Jan A. Burger,Susan O'Brien,William G. Wierda,Zeev Estrov,Gracy Zacharian,Alessandra Ferrajoli +7 more
TL;DR: The anti-tumoral activity of lenalidomide occurs via multiple mechanisms, including repair of chronic lymphocytic leukemia-induced immune defects, and it is hypothesized that it would be an effective and safe consolidation strategy in patients with chronic lymphocyte leukemia (CLL).
Journal ArticleDOI
Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Farhad Ravandi,Jan A. Burger,Gautam Borthakur,Jorge E. Cortes +5 more
TL;DR: The incidence of bleeding episodes associated with dasatinib therapy among 138 consecutive pts with CML treated at the authors' institution between November 2003 and January 2006 after failure or resistance to imatinib was evaluated.
Journal ArticleDOI
Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies
Paul A. Hamlin,Ian W. Flinn,Nina D. Wagner-Johnston,Jan A. Burger,Glenn C. Michelson,Anjali Pandey,Matt Birrell,Greg Coffey,Janet M. Leeds,John T. Curnutte,Manish R. Patel +10 more
TL;DR: Cerdulatinib continues to demonstrate a favorable PK profile and good tolerability at high levels of SYK and JAK inhibition and appears to induce apoptosis in the majority of B cell lymphoma cell lines tested.